CLINICAL TRIALS PROFILE FOR LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00309608 ↗ | Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes | Completed | Boehringer Ingelheim | Phase 2 | 2006-04-01 | The objective of the study is to test the efficacy, safety and tolerability of several doses of BI 1356 BS (1, 5, or 10 mg taken once daily) compared to placebo given for 12 weeks together with metformin in patients with type 2 diabetes mellitus who are not at goal with their HbA1c levels. In addition, there will be an unblinded treatment arm with glimepiride as add-on therapy to metformin for comparison. The influence of several factors (gender, age, weight, race, etc.) on the bioavailability and efficacy of BI 1356 BS will also be tested in this study. |
| NCT00601250 ↗ | Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes | Completed | Boehringer Ingelheim | Phase 3 | 2008-01-01 | The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control |
| NCT00602472 ↗ | BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes | Completed | Boehringer Ingelheim | Phase 3 | 2008-02-01 | The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with a sulphonylurea in patients with type 2 diabetes mellitus with insufficient glycaemic control. |
| NCT00798161 ↗ | Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design | Completed | Boehringer Ingelheim | Phase 3 | 2008-12-01 | The objective of the randomised part of the study is to investigate the efficacy and safety of BI 1356 plus metformin compared to BI 1356 or metformin alone given for 24 weeks to drug naive or previously treated (4 weeks wash-out, 2 weeks placebo run-in) type 2 diabetic patients with insufficient glycaemic control. For the open-label part of the study the objective is to estimate the efficacy and safety of BI 1356 and metformin in type 2 diabetic patients with very poor glycaemic control for 24 weeks |
| NCT00915772 ↗ | Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid | Completed | Boehringer Ingelheim | Phase 3 | 2009-06-01 | A phase III randomised, double-blind parallel group extension study to investigate the efficacy and safety of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 mg or of linagliptin 2.5 mg + metformin 1000 mg versus monotherapy with metformin 1000 mg twice daily over 54 weeks in type 2 diabetic patients previously completing the double-blind part of study 1218.46 |
| NCT00996658 ↗ | Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone | Completed | Eli Lilly and Company | Phase 3 | 2009-10-01 | The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (5 mg once daily) compared to placebo given for 24 weeks as add on therapy to metformin in combination with pioglitazone in patients with type 2 diabetes mellitus with insufficient glycaemic control. |
| NCT00996658 ↗ | Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone | Completed | Boehringer Ingelheim | Phase 3 | 2009-10-01 | The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (5 mg once daily) compared to placebo given for 24 weeks as add on therapy to metformin in combination with pioglitazone in patients with type 2 diabetes mellitus with insufficient glycaemic control. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
Condition Name
Clinical Trial Locations for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
Sponsor Name
